• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于机器学习的非酒精性脂肪性肝病相关肝细胞癌生存及危险因素评估以优化患者管理

Machine Learning-Based Assessment of Survival and Risk Factors in Non-Alcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma for Optimized Patient Management.

作者信息

Suárez Miguel, Gil-Rojas Sergio, Martínez-Blanco Pablo, Torres Ana M, Ramón Antonio, Blasco-Segura Pilar, Torralba Miguel, Mateo Jorge

机构信息

Gastroenterology Department, Virgen de la Luz Hospital, 16002 Cuenca, Spain.

Medical Analysis Expert Group, Institute of Technology, Universidad de Castilla-La Mancha, 16071 Cuenca, Spain.

出版信息

Cancers (Basel). 2024 Mar 10;16(6):1114. doi: 10.3390/cancers16061114.

DOI:10.3390/cancers16061114
PMID:38539449
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10969326/
Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide, with an incidence that is exponentially increasing. Hepatocellular carcinoma (HCC) is the most frequent primary tumor. There is an increasing relationship between these entities due to the potential risk of developing NAFLD-related HCC and the prevalence of NAFLD. There is limited evidence regarding prognostic factors at the diagnosis of HCC. This study compares the prognosis of HCC in patients with NAFLD against other etiologies. It also evaluates the prognostic factors at the diagnosis of these patients. For this purpose, a multicenter retrospective study was conducted involving a total of 191 patients. Out of the total, 29 presented NAFLD-related HCC. The extreme gradient boosting (XGB) method was employed to develop the reference predictive model. Patients with NAFLD-related HCC showed a worse prognosis compared to other potential etiologies of HCC. Among the variables with the worst prognosis, alcohol consumption in NAFLD patients had the greatest weight within the developed predictive model. In comparison with other studied methods, XGB obtained the highest values for the analyzed metrics. In conclusion, patients with NAFLD-related HCC and alcohol consumption, obesity, cirrhosis, and clinically significant portal hypertension (CSPH) exhibited a worse prognosis than other patients. XGB developed a highly efficient predictive model for the assessment of these patients.

摘要

非酒精性脂肪性肝病(NAFLD)是全球最常见的慢性肝病,其发病率呈指数级增长。肝细胞癌(HCC)是最常见的原发性肿瘤。由于发生NAFLD相关HCC的潜在风险以及NAFLD的患病率,这些疾病之间的关联日益增加。关于HCC诊断时的预后因素,证据有限。本研究比较了NAFLD患者与其他病因患者的HCC预后。它还评估了这些患者诊断时的预后因素。为此,进行了一项多中心回顾性研究,共纳入191例患者。其中,29例为NAFLD相关HCC。采用极端梯度提升(XGB)方法建立参考预测模型。与HCC的其他潜在病因相比,NAFLD相关HCC患者的预后较差。在预后最差的变量中,NAFLD患者的饮酒情况在已建立的预测模型中权重最大。与其他研究方法相比,XGB在分析指标上获得了最高值。总之,与其他患者相比,患有NAFLD相关HCC且有饮酒、肥胖、肝硬化和临床显著门静脉高压(CSPH)的患者预后更差。XGB建立了一个高效的预测模型来评估这些患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34aa/10969326/73e56bc241e2/cancers-16-01114-g005a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34aa/10969326/f9678293ddba/cancers-16-01114-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34aa/10969326/e7b30378dff6/cancers-16-01114-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34aa/10969326/a21664a4a50a/cancers-16-01114-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34aa/10969326/ac56f1607efc/cancers-16-01114-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34aa/10969326/73e56bc241e2/cancers-16-01114-g005a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34aa/10969326/f9678293ddba/cancers-16-01114-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34aa/10969326/e7b30378dff6/cancers-16-01114-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34aa/10969326/a21664a4a50a/cancers-16-01114-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34aa/10969326/ac56f1607efc/cancers-16-01114-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34aa/10969326/73e56bc241e2/cancers-16-01114-g005a.jpg

相似文献

1
Machine Learning-Based Assessment of Survival and Risk Factors in Non-Alcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma for Optimized Patient Management.基于机器学习的非酒精性脂肪性肝病相关肝细胞癌生存及危险因素评估以优化患者管理
Cancers (Basel). 2024 Mar 10;16(6):1114. doi: 10.3390/cancers16061114.
2
Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis.非肝硬化非酒精性脂肪性肝病(NAFLD)患者肝细胞癌(HCC)的特征
Hepatol Int. 2016 Jul;10(4):632-9. doi: 10.1007/s12072-015-9679-0. Epub 2015 Nov 11.
3
Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease.非酒精性脂肪性肝病所致肝细胞癌的流行趋势。
Expert Rev Gastroenterol Hepatol. 2019 Feb;13(2):179-187. doi: 10.1080/17474124.2019.1549989. Epub 2018 Dec 29.
4
Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.非酒精性脂肪性肝病、代谢风险因素与肝细胞癌:一个悬而未决的问题。
World J Gastroenterol. 2015 Apr 14;21(14):4103-10. doi: 10.3748/wjg.v21.i14.4103.
5
Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link.非酒精性脂肪性肝病与肝细胞癌:一个有趣关联的临床挑战。
World J Gastroenterol. 2022 Jan 21;28(3):310-331. doi: 10.3748/wjg.v28.i3.310.
6
Differentiation of clinical patterns and survival outcomes of hepatocellular carcinoma on hepatitis B and nonalcoholic fatty liver disease.乙型肝炎和非酒精性脂肪性肝病患者肝癌的临床特征和生存结局的差异。
J Chin Med Assoc. 2021 Jun 1;84(6):606-613. doi: 10.1097/JCMA.0000000000000530.
7
Epidemiology of non-alcoholic fatty liver disease-related hepatocellular carcinoma and its implications.非酒精性脂肪性肝病相关肝细胞癌的流行病学及其影响
JGH Open. 2018 Jul 17;2(5):235-241. doi: 10.1002/jgh3.12070. eCollection 2018 Oct.
8
Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis.非酒精性脂肪性肝病在没有明显肝硬化的情况下进展为肝细胞癌。
Int J Cancer. 2011 May 15;128(10):2436-43. doi: 10.1002/ijc.25797. Epub 2011 Mar 14.
9
Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Current Progresses and Challenges.非酒精性脂肪性肝病中的肝细胞癌:当前进展与挑战
J Clin Transl Hepatol. 2022 Oct 28;10(5):955-964. doi: 10.14218/JCTH.2021.00586. Epub 2022 May 18.
10
Hepatocellular Carcinoma in Non Alcoholic Fatty Liver Disease.非酒精性脂肪性肝病中的肝细胞癌。
Curr Pharm Des. 2020;26(32):3909-3914. doi: 10.2174/1381612826666200429093648.

引用本文的文献

1
Machine learning for predicting all-cause mortality of metabolic dysfunction-associated fatty liver disease: a longitudinal study based on NHANES.用于预测代谢功能障碍相关脂肪性肝病全因死亡率的机器学习:一项基于美国国家健康与营养检查调查(NHANES)的纵向研究
BMC Gastroenterol. 2025 May 15;25(1):376. doi: 10.1186/s12876-025-03946-4.
2
Application of the Random Forest Algorithm for Accurate Bipolar Disorder Classification.随机森林算法在双相情感障碍精确分类中的应用。
Life (Basel). 2025 Mar 3;15(3):394. doi: 10.3390/life15030394.
3
Role of Artificial Intelligence in Identifying Vital Biomarkers with Greater Precision in Emergency Departments During Emerging Pandemics.

本文引用的文献

1
From Non-Alcoholic Steatohepatitis (NASH) to Hepatocellular Carcinoma (HCC): Epidemiology, Incidence, Predictions, Risk Factors, and Prevention.从非酒精性脂肪性肝炎(NASH)到肝细胞癌(HCC):流行病学、发病率、预测、危险因素及预防
Cancers (Basel). 2023 Nov 17;15(22):5458. doi: 10.3390/cancers15225458.
2
Gene Variants Implicated in Steatotic Liver Disease: Opportunities for Diagnostics and Therapeutics.与脂肪性肝病相关的基因变异:诊断与治疗的机遇
Biomedicines. 2023 Oct 17;11(10):2809. doi: 10.3390/biomedicines11102809.
3
Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors.
人工智能在新发大流行期间急诊科更精准识别关键生物标志物中的作用
Int J Mol Sci. 2025 Jan 16;26(2):722. doi: 10.3390/ijms26020722.
4
Inflammation and Immunity in Liver Neoplasms: Implications for Future Therapeutic Strategies.肝脏肿瘤中的炎症与免疫:对未来治疗策略的启示
Mol Cancer Ther. 2025 Feb 4;24(2):188-199. doi: 10.1158/1535-7163.MCT-23-0726.
5
Assessment of Albumin-Incorporating Scores at Hepatocellular Carcinoma Diagnosis Using Machine Learning Techniques: An Evaluation of Prognostic Relevance.使用机器学习技术评估肝细胞癌诊断时的白蛋白整合评分:预后相关性评估
Bioengineering (Basel). 2024 Jul 28;11(8):762. doi: 10.3390/bioengineering11080762.
6
Innovation through Artificial Intelligence in Triage Systems for Resource Optimization in Future Pandemics.通过人工智能优化分诊系统以在未来大流行中实现资源优化创新。
Biomimetics (Basel). 2024 Jul 18;9(7):440. doi: 10.3390/biomimetics9070440.
7
Prognostic Impact of Metabolic Syndrome and Steatotic Liver Disease in Hepatocellular Carcinoma Using Machine Learning Techniques.运用机器学习技术探讨代谢综合征和脂肪性肝病对肝细胞癌的预后影响
Metabolites. 2024 May 27;14(6):305. doi: 10.3390/metabo14060305.
代谢功能障碍相关脂肪性肝病相关肝肿瘤的病理学与发病机制
Biomedicines. 2023 Oct 12;11(10):2761. doi: 10.3390/biomedicines11102761.
4
Personalized Risk Assessment of Hepatic Fibrosis after Cholecystectomy in Metabolic-Associated Steatotic Liver Disease: A Machine Learning Approach.代谢相关脂肪性肝病患者胆囊切除术后肝纤维化的个性化风险评估:一种机器学习方法
J Clin Med. 2023 Oct 12;12(20):6489. doi: 10.3390/jcm12206489.
5
Risk factors for fibrosis progression in non-alcoholic steatohepatitis: Analysis of the European cohort in the real-world GAIN study.非酒精性脂肪性肝炎纤维化进展的风险因素:真实世界 GAIN 研究中欧洲队列的分析。
Gastroenterol Hepatol. 2024 May;47(5):463-472. doi: 10.1016/j.gastrohep.2023.10.005. Epub 2023 Oct 27.
6
Combining bulk and single-cell RNA-sequencing data to develop an NK cell-related prognostic signature for hepatocellular carcinoma based on an integrated machine learning framework.结合 bulk 和单细胞 RNA-seq 数据,基于集成机器学习框架开发用于肝细胞癌的 NK 细胞相关预后特征。
Eur J Med Res. 2023 Aug 30;28(1):306. doi: 10.1186/s40001-023-01300-6.
7
MRI-Based Radiomics and Deep Learning in Biological Characteristics and Prognosis of Hepatocellular Carcinoma: Opportunities and Challenges.基于 MRI 的放射组学和深度学习在肝细胞癌生物学特征和预后中的应用:机遇与挑战。
J Magn Reson Imaging. 2024 Mar;59(3):767-783. doi: 10.1002/jmri.28982. Epub 2023 Aug 30.
8
Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?脂肪性肝病:代谢功能障碍、酒精,还是两者皆有?
Biomedicines. 2023 Jul 26;11(8):2108. doi: 10.3390/biomedicines11082108.
9
A Machine Learning Method to Identify the Risk Factors for Liver Fibrosis Progression in Nonalcoholic Steatohepatitis.一种机器学习方法,用于识别非酒精性脂肪性肝炎肝纤维化进展的危险因素。
Dig Dis Sci. 2023 Sep;68(9):3801-3809. doi: 10.1007/s10620-023-08031-y. Epub 2023 Jul 21.
10
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.多学会专家共识:新脂肪性肝病命名。
Ann Hepatol. 2024 Jan-Feb;29(1):101133. doi: 10.1016/j.aohep.2023.101133. Epub 2023 Jun 24.